CVE:HTL

Hamilton Thorne Competitors

C$1.75
+0.02 (+1.16 %)
(As of 04/15/2021 03:54 PM ET)
Add
Compare
Today's Range
C$1.71
Now: C$1.75
C$1.75
50-Day Range
C$1.54
MA: C$1.68
C$1.81
52-Week Range
C$1.02
Now: C$1.75
C$1.84
Volume27,538 shs
Average Volume138,991 shs
Market CapitalizationC$243.07 million
P/E Ratio194.44
Dividend YieldN/A
BetaN/A

Competitors

Hamilton Thorne (CVE:HTL) Vs. VMD, TMD, PTQ, PHM, HSM, and ASG

Should you be buying HTL stock or one of its competitors? Companies in the industry of "medical devices" are considered alternatives and competitors to Hamilton Thorne, including Viemed Healthcare (VMD), Titan Medical (TMD), Protech Home Medical (PTQ), Protech Home Medical (PHM), Helius Medical Technologies (HSM), and Aurora Spine (ASG).

Viemed Healthcare (TSE:VMD) and Hamilton Thorne (CVE:HTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Viemed Healthcare and Hamilton Thorne, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viemed Healthcare01002.00
Hamilton Thorne00403.00

Hamilton Thorne has a consensus price target of C$1.87, indicating a potential upside of 6.86%. Given Hamilton Thorne's stronger consensus rating and higher possible upside, analysts plainly believe Hamilton Thorne is more favorable than Viemed Healthcare.

Profitability

This table compares Viemed Healthcare and Hamilton Thorne's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viemed HealthcareN/AN/AN/A
Hamilton ThorneN/AN/AN/A

Earnings and Valuation

This table compares Viemed Healthcare and Hamilton Thorne's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viemed HealthcareC$131.31 million3.69C$38.69 millionC$0.9812.54
Hamilton ThorneC$39.78 million6.11C$1.25 millionC$0.01194.44

Viemed Healthcare has higher revenue and earnings than Hamilton Thorne. Viemed Healthcare is trading at a lower price-to-earnings ratio than Hamilton Thorne, indicating that it is currently the more affordable of the two stocks.

Summary

Hamilton Thorne beats Viemed Healthcare on 5 of the 8 factors compared between the two stocks.

Titan Medical (TSE:TMD) and Hamilton Thorne (CVE:HTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Titan Medical and Hamilton Thorne, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Titan Medical0000N/A
Hamilton Thorne00403.00

Hamilton Thorne has a consensus price target of C$1.87, indicating a potential upside of 6.86%. Given Hamilton Thorne's higher possible upside, analysts plainly believe Hamilton Thorne is more favorable than Titan Medical.

Profitability

This table compares Titan Medical and Hamilton Thorne's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Titan MedicalN/AN/AN/A
Hamilton ThorneN/AN/AN/A

Earnings and Valuation

This table compares Titan Medical and Hamilton Thorne's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Titan MedicalC$20 million11.17C$-49,505,300.00C($0.45)-4.51
Hamilton ThorneC$39.78 million6.11C$1.25 millionC$0.01194.44

Hamilton Thorne has higher revenue and earnings than Titan Medical. Titan Medical is trading at a lower price-to-earnings ratio than Hamilton Thorne, indicating that it is currently the more affordable of the two stocks.

Summary

Hamilton Thorne beats Titan Medical on 6 of the 7 factors compared between the two stocks.

Protech Home Medical (CVE:PTQ) and Hamilton Thorne (CVE:HTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Protech Home Medical and Hamilton Thorne, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Protech Home Medical00503.00
Hamilton Thorne00403.00

Protech Home Medical presently has a consensus price target of C$2.58, indicating a potential upside of 21.28%. Hamilton Thorne has a consensus price target of C$1.87, indicating a potential upside of 6.86%. Given Protech Home Medical's higher possible upside, equities analysts plainly believe Protech Home Medical is more favorable than Hamilton Thorne.

Profitability

This table compares Protech Home Medical and Hamilton Thorne's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Protech Home MedicalN/AN/AN/A
Hamilton ThorneN/AN/AN/A

Earnings and Valuation

This table compares Protech Home Medical and Hamilton Thorne's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protech Home MedicalC$82.22 million2.92C$-5,417,568.00C($0.05)-44.38
Hamilton ThorneC$39.78 million6.11C$1.25 millionC$0.01194.44

Hamilton Thorne has lower revenue, but higher earnings than Protech Home Medical. Protech Home Medical is trading at a lower price-to-earnings ratio than Hamilton Thorne, indicating that it is currently the more affordable of the two stocks.

Summary

Hamilton Thorne beats Protech Home Medical on 4 of the 7 factors compared between the two stocks.

Protech Home Medical (CVE:PHM) and Hamilton Thorne (CVE:HTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Protech Home Medical and Hamilton Thorne, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Protech Home Medical0000N/A
Hamilton Thorne00403.00

Hamilton Thorne has a consensus price target of C$1.87, indicating a potential upside of 6.86%. Given Hamilton Thorne's higher possible upside, analysts plainly believe Hamilton Thorne is more favorable than Protech Home Medical.

Profitability

This table compares Protech Home Medical and Hamilton Thorne's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Protech Home MedicalN/AN/AN/A
Hamilton ThorneN/AN/AN/A

Earnings and Valuation

This table compares Protech Home Medical and Hamilton Thorne's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protech Home MedicalC$77.14 million0.62C$833,022.00C$0.0057.50
Hamilton ThorneC$39.78 million6.11C$1.25 millionC$0.01194.44

Hamilton Thorne has lower revenue, but higher earnings than Protech Home Medical. Protech Home Medical is trading at a lower price-to-earnings ratio than Hamilton Thorne, indicating that it is currently the more affordable of the two stocks.

Summary

Hamilton Thorne beats Protech Home Medical on 6 of the 7 factors compared between the two stocks.

Helius Medical Technologies (TSE:HSM) and Hamilton Thorne (CVE:HTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Helius Medical Technologies and Hamilton Thorne, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Helius Medical Technologies0000N/A
Hamilton Thorne00403.00

Hamilton Thorne has a consensus price target of C$1.87, indicating a potential upside of 6.86%. Given Hamilton Thorne's higher possible upside, analysts plainly believe Hamilton Thorne is more favorable than Helius Medical Technologies.

Earnings and Valuation

This table compares Helius Medical Technologies and Hamilton Thorne's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helius Medical TechnologiesC$661,000.0073.42C$-34,262,886.00C($14.83)-1.42
Hamilton ThorneC$39.78 million6.11C$1.25 millionC$0.01194.44

Hamilton Thorne has higher revenue and earnings than Helius Medical Technologies. Helius Medical Technologies is trading at a lower price-to-earnings ratio than Hamilton Thorne, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Helius Medical Technologies and Hamilton Thorne's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Helius Medical TechnologiesN/AN/AN/A
Hamilton ThorneN/AN/AN/A

Summary

Hamilton Thorne beats Helius Medical Technologies on 6 of the 7 factors compared between the two stocks.

Hamilton Thorne (CVE:HTL) and Aurora Spine (CVE:ASG) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.

Analyst Ratings

This is a summary of current recommendations and price targets for Hamilton Thorne and Aurora Spine, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hamilton Thorne00403.00
Aurora Spine0000N/A

Hamilton Thorne currently has a consensus target price of C$1.87, indicating a potential upside of 6.86%. Given Hamilton Thorne's higher possible upside, analysts plainly believe Hamilton Thorne is more favorable than Aurora Spine.

Valuation & Earnings

This table compares Hamilton Thorne and Aurora Spine's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hamilton ThorneC$39.78 million6.11C$1.25 millionC$0.01194.44
Aurora SpineC$8.84 million4.83C$-1,052,790.00C($0.02)-40.53

Hamilton Thorne has higher revenue and earnings than Aurora Spine. Aurora Spine is trading at a lower price-to-earnings ratio than Hamilton Thorne, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Hamilton Thorne and Aurora Spine's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hamilton ThorneN/AN/AN/A
Aurora SpineN/AN/AN/A

Summary

Hamilton Thorne beats Aurora Spine on 7 of the 7 factors compared between the two stocks.


Hamilton Thorne Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
VMD
Viemed Healthcare
0.3$12.26+0.7%C$485.03 millionC$131.31 million12.54
TMD
Titan Medical
0.8$2.04+2.5%C$223.43 millionC$20 million-4.51
Protech Home Medical logo
PTQ
Protech Home Medical
1.2$2.13+0.9%C$94.56 millionC$82.22 million-44.38
PHM
Protech Home Medical
0.5$0.12+4.3%C$50.12 millionC$77.14 million57.50Gap Up
HSM
Helius Medical Technologies
0.5$21.00+3.6%C$48.53 millionC$661,000.00-1.42
ASG
Aurora Spine
0.6$0.77+1.3%C$8.31 millionC$8.84 million-40.53
BLO
Cannabix Technologies
0.5N/AN/AC$0.00N/A0.00Gap Up
ORTH
Ortho Regenerative Technologies
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
Smith & Nephew logo
SNN
Smith & Nephew
0.6N/AN/A$0.00N/A0.00News Coverage
VMD
Viemed Healthcare
0.5$4.95+2.0%C$0.00N/A0.00Gap Up
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.